Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The price of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) closed at $164.97 in the last session, up 1.67% from day before closing price of $162.26. In other words, the price has increased by $1.67 from its previous closing price. On the day, 1.38 million shares were traded. JAZZ stock price reached its highest trading level at $166.085 during the session, while it also had its lowest trading level at $161.03.
Ratios:
We take a closer look at JAZZ’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.90 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 7.50. For the most recent quarter (mrq), Quick Ratio is recorded 1.44 and its Current Ratio is at 1.65. In the meantime, Its Debt-to-Equity ratio is 1.37 whereas as Long-Term Debt/Eq ratio is at 1.11.
On July 15, 2025, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $152.
UBS Upgraded its Neutral to Buy on March 07, 2025, whereas the target price for the stock was revised from $145 to $179.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 09 ’25 when MARY ELIZABETH HENDERSON bought 2,238 shares for $169.51 per share.
Carr Patricia sold 4,660 shares of JAZZ for $797,783 on Dec 05 ’25. The SVP, Chief Accounting Officer now owns 7,012 shares after completing the transaction at $171.20 per share. On Dec 05 ’25, another insider, PATRICIA CARR, who serves as the Officer of the company, bought 4,660 shares for $171.20 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JAZZ now has a Market Capitalization of 10024421376 and an Enterprise Value of 13407310848. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.14. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.41 while its Price-to-Book (P/B) ratio in mrq is 2.53. Its current Enterprise Value per Revenue stands at 3.225 whereas that against EBITDA is 8.338.
Stock Price History:
The Beta on a monthly basis for JAZZ is 0.28, which has changed by 0.31278312 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, JAZZ has reached a high of $182.99, while it has fallen to a 52-week low of $95.49. The 50-Day Moving Average of the stock is 10.71%, while the 200-Day Moving Average is calculated to be 31.18%.
Shares Statistics:
According to the various share statistics, JAZZ traded on average about 988.06K shares per day over the past 3-months and 1007830 shares per day over the past 10 days. A total of 60.74M shares are outstanding, with a floating share count of 57.99M. Insiders hold about 4.56% of the company’s shares, while institutions hold 100.49% stake in the company. Shares short for JAZZ as of 1764288000 were 4974908 with a Short Ratio of 5.04, compared to 1761868800 on 5116514. Therefore, it implies a Short% of Shares Outstanding of 4974908 and a Short% of Float of 9.46.
Earnings Estimates
Current recommendations for the stock of the company come from 16.0 analysts. The consensus estimate for the next quarter is $4.44, with high estimates of $5.96 and low estimates of $3.52.
Analysts are recommending an EPS of between $8.82 and $7.71 for the fiscal current year, implying an average EPS of $8.11. EPS for the following year is $22.71, with 16.0 analysts recommending between $30.05 and $19.92.
Revenue Estimates
According to 15 analysts,. The current quarter’s revenue is expected to be $1.16B. It ranges from a high estimate of $1.22B to a low estimate of $1.11B. As of. The current estimate, Jazz Pharmaceuticals plc’s year-ago sales were $1.09BFor the next quarter, 15 analysts are estimating revenue of $975.87M. There is a high estimate of $1.1B for the next quarter, whereas the lowest estimate is $899M.
A total of 17 analysts have provided revenue estimates for JAZZ’s current fiscal year. The highest revenue estimate was $4.29B, while the lowest revenue estimate was $4.18B, resulting in an average revenue estimate of $4.23B. In the same quarter a year ago, actual revenue was $4.07BBased on 17 analysts’ estimates, the company’s revenue will be $4.52B in the next fiscal year. The high estimate is $4.98B and the low estimate is $4.12B.
